WASHINGTON - A month after approving a new drug to treat
Alzheimer's disease, US regulators on Thursday issued new prescribing
instructions that will likely limit its use.
The Food and Drug Administration (FDA) said the goal of the
change is to respond to confusion among doctors and patients about who should
use the drug, whose approval last month sparked an intense backlash.
Post a Comment
We want to know your comments and concerns. Remember: Respect distinguishes us, education makes us different...